The stock of Second Sight Medical Products Inc (NASDAQ:EYES) is a huge mover today! About 221,992 shares traded hands. Second Sight Medical Products Inc (NASDAQ:EYES) has declined 56.42% since April 14, 2016 and is downtrending. It has underperformed by 61.11% the S&P500.
The move comes after 7 months positive chart setup for the $110.70M company. It was reported on Nov, 16 by Barchart.com. We have $6.51 PT which if reached, will make NASDAQ:EYES worth $185.98 million more.
According to Zacks Investment Research, “Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California.”
More recent Second Sight Medical Products Inc (NASDAQ:EYES) news were published by: Businesswire.com which released: “Second Sight Medical Products, Inc. Announces Completion of Oversubscribed …” on June 01, 2016. Also Latimes.com published the news titled: “With ‘bionic eye’ booming, Second Sight is on analysts’ radar” on March 16, 2015. Seekingalpha.com‘s news article titled: “Second Sight Medical Products ‘ (EYES) CEO Will McGuire on Q1 2016 Results …” with publication date: May 01, 2016 was also an interesting one.
EYES Company Profile
Second Sight Medical Products, Inc., incorporated on May 22, 2003, is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.